cor2ed
engage checkpoint medical linkedin twitter
bg

Targeting Advanced Prostate Cancer with PARP inhibitors: Who, When and How?

Targeting Advanced Prostate Cancer with PARP inhibitors: Who, When and How?

On-demand educational resources (e-learning, video and slide set) are now available following a successful GU CONNECT Experts Knowledge Share event on the topic of targeting advanced prostate cancer with PARP inhibitors: Who, When and How?

On-demand educational resources (e-learning, video and slide set) are now available following a successful GU CONNECT Experts Knowledge Share event on the topic of targeting advanced prostate cancer with PARP inhibitors: Who, When and How?

Prof. Gerhardt Attard, Assoc. Prof. Tanya Dorff, Prof. Fred Saad

Take the e-learning and claim your CME credit. Watch the video and download the slides.

Portrait of Gerhardt Attard
Prof. Gerhardt Attard

Medical Oncologist

University College London Cancer Institute

United Kingdom (UK)

Portrait of Tanya Dorff
Assoc. Prof. Tanya Dorff

Medical Oncologist

City of Hope Comprehensive Cancer Center

United States (US)

Image of Prof. Fred Saad
Prof. Fred Saad

Professor and Chairman of Urology, Director of GU Oncology Raymond Garneau Chair in Prostate Cancer

University of Montreal Hospital Center, Canada

Canada

preview next

time BluePrint Resource | open 60 min |accreditation: EACCME

I agree that this educational programme:

Was valuable to me:

1/3

Targeting Advanced Prostate Cancer with PARP inhibitors: Who, When and How?

Following on from the success of the Experts Knowledge Share meeting, GU CONNECT has produced an interactive e-learning, slide set and video.
 
GU CONNECT members, Assoc. Prof. Tanya Dorff (USA) and Prof. Gerhardt Attard (UK) along with guest expert Prof. Fred Saad (Canada) were joined by participants from around the world to discuss targeting advanced prostate cancer with PARP inhibitors: Who, When and How?
 
There was a very interesting and dynamic discussion about:
  • The efficacy and safety profiles of PARP inhibitors for patients with prostate cancer and the safety profile in other tumour types
  • Implementation of testing strategies to predict if the prostate cancer is likely to respond to a PARP inhibitor or some other treatment
  • Data of combination studies with PARP inhibitors, the appropriate implementation in treatment strategies and the impact on clinical practice

Take the e-learning and claim your CME credit. 

Watch the Experts Knowledge Share event and download the slides above.

Meeting Video Chapters

Chapter 1 00:00 Faculty and Disclaimer
Chapter 2 00:28 Overview and scene-setting - Prof. Fred Saad
Chapter 3 02:08 Who should you treat? - Prof. Gerhardt Attard
Chapter 4 18:55 Why you should treat - Assoc. Prof. Tanya Dorff
Chapter 5 33:11 Combination therapy with PARP inhibitors - Prof. Fred Saad
Chapter 6 46:48 Questions for panel
Chapter 7 52:13 Future perspectives and summary - Prof Fred Saad

Other programmes of interest

Other programmes developed by Prof. Gerhardt Attard

Other programmes developed by Assoc. Prof. Tanya Dorff